The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...
The company’s active-controlled, open-label BREAKWATER trial (NCT05217446) evaluating a combination of Pfizer’s Braftovi (encorafenib), Eli Lilly’s Erbitux (cetuximab) and mFOLFOX6 ...
In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.
The new results from the BREAKWATER study – which is testing the combination of BRAF inhibitor Braftovi (encorafenib) with Eli Lilly's Erbitux (cetuximab) and chemotherapy – showed a ...
Hosted on MSN1mon
Pfizer's BRAFTOVI shows promise in colorectal cancer trialThe BREAKWATER trial, a randomized, active-controlled, open-label, multicenter study, compared the efficacy of BRAFTOVI with cetuximab and mFOLFOX6 against standard chemotherapy with or without ...
The safety profile of Braftovi in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent. Pfizer will share these latest results ...
At the time of the ORR analysis, the safety profile of Braftovi in combination with Lilly’s Erbitux and mFOLFOX6 remained consistent with the established safety profiles of each agent.
The company announced top-tier results from its Phase 3 BREAKWATER trial of BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer (mCRC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback